Biomarkers in localized prostate cancer

Matteo Ferro, Carlo Buonerba, Daniela Terracciano, Giuseppe Lucarelli, Vincenzo Cosimato, Danilo Bottero, Victor M. Deliu, Pasquale Ditonno, Sisto Perdonà, Riccardo Autorino, Ioman Coman, Sabino De Placido, Giuseppe Di Lorenzo, Ottavio De Cobelli

Research output: Contribution to journalArticle

Abstract

Biomarkers can improve prostate cancer diagnosis and treatment. Accuracy of prostate-specific antigen (PSA) for early diagnosis of prostate cancer is not satisfactory, as it is an organ- but not cancer-specific biomarker, and it can be improved by using models that incorporate PSA along with other test results, such as prostate cancer antigen 3, the molecular forms of PSA (proPSA, benign PSA and intact PSA), as well as kallikreins. Recent reports suggest that new tools may be provided by metabolomic studies as shown by preliminary data on sarcosine. Additional molecular biomarkers have been identified by the use of genomics, proteomics and metabolomics. We review the most relevant biomarkers for early diagnosis and management of localized prostate cancer.

Original languageEnglish
Pages (from-to)399-411
Number of pages13
JournalFuture Oncology
Volume12
Issue number3
DOIs
Publication statusPublished - Feb 1 2016

    Fingerprint

Keywords

  • biomarkers
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ferro, M., Buonerba, C., Terracciano, D., Lucarelli, G., Cosimato, V., Bottero, D., Deliu, V. M., Ditonno, P., Perdonà, S., Autorino, R., Coman, I., De Placido, S., Di Lorenzo, G., & De Cobelli, O. (2016). Biomarkers in localized prostate cancer. Future Oncology, 12(3), 399-411. https://doi.org/10.2217/fon.15.318